ECSP099612A - Derivados de bencimidazol y sus métodos de uso - Google Patents

Derivados de bencimidazol y sus métodos de uso

Info

Publication number
ECSP099612A
ECSP099612A EC2009009612A ECSP099612A ECSP099612A EC SP099612 A ECSP099612 A EC SP099612A EC 2009009612 A EC2009009612 A EC 2009009612A EC SP099612 A ECSP099612 A EC SP099612A EC SP099612 A ECSP099612 A EC SP099612A
Authority
EC
Ecuador
Prior art keywords
methods
compounds
bencimidazol
derivatives
igt
Prior art date
Application number
EC2009009612A
Other languages
English (en)
Inventor
Robert G Aslantan
Jean E Lachowicz
Michael Y Berlin
Joyce J Hwa
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP099612A publication Critical patent/ECSP099612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I): (I)a composiciones que comprenden los compuestos y a métodos de uso de los compuestos para tratar o prevenir dolor, diabetes, una complicación diabética, tolerancia a glucosa alterada (IGT) o glucosa en ayunas alterada (IGT) en un paciente.
EC2009009612A 2007-03-02 2009-09-01 Derivados de bencimidazol y sus métodos de uso ECSP099612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90445307P 2007-03-02 2007-03-02

Publications (1)

Publication Number Publication Date
ECSP099612A true ECSP099612A (es) 2009-10-30

Family

ID=39386454

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009612A ECSP099612A (es) 2007-03-02 2009-09-01 Derivados de bencimidazol y sus métodos de uso

Country Status (18)

Country Link
US (1) US20100144591A1 (es)
EP (1) EP2114402A2 (es)
JP (1) JP2010520201A (es)
KR (1) KR20090127902A (es)
CN (1) CN101674827A (es)
AR (1) AR065495A1 (es)
AU (1) AU2008223513A1 (es)
BR (1) BRPI0808707A2 (es)
CA (1) CA2679809A1 (es)
CL (1) CL2008000593A1 (es)
EC (1) ECSP099612A (es)
IL (1) IL200639A0 (es)
MX (1) MX2009009416A (es)
PE (1) PE20090111A1 (es)
RU (1) RU2009136263A (es)
TW (1) TW200843756A (es)
WO (1) WO2008108958A2 (es)
ZA (1) ZA200906062B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537998A (ja) * 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
CN102361857B (zh) * 2008-09-26 2015-09-16 默沙东公司 可用作抗糖尿病剂的环状苯并咪唑衍生物
EP2404902A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TW201121957A (en) 2009-11-18 2011-07-01 Astrazeneca Ab Benzoimidazole compounds and uses thereof
MX2012007367A (es) 2009-12-30 2013-04-03 Arqule Inc Compuestos substituidos de imidazopiridinilo-aminopiridina.
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
JP5790440B2 (ja) 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
UA111075C2 (uk) * 2011-02-25 2016-03-25 Еррей Біофарма Інк. Триазолопіридинові сполуки як інгібітори кінази рім
JP2014114212A (ja) * 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
EP2723741B8 (en) 2011-06-24 2016-09-21 ArQule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2014031445A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US20140371238A1 (en) * 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN104860919B (zh) * 2015-03-26 2017-11-10 天津药物研究院有限公司 含哌啶的苯并咪唑衍生物及其制备方法和用途
WO2017082393A1 (ja) * 2015-11-12 2017-05-18 学校法人 聖マリアンナ医科大学 緑内障予防治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
PL373586A1 (en) * 2002-01-11 2005-09-05 Abbott Laboratories Histamine-3 receptor ligands for diabetic conditions
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
US7332604B2 (en) * 2005-09-20 2008-02-19 Schering Corporation 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição

Also Published As

Publication number Publication date
RU2009136263A (ru) 2011-04-10
BRPI0808707A2 (pt) 2014-09-09
MX2009009416A (es) 2009-09-11
CN101674827A (zh) 2010-03-17
CA2679809A1 (en) 2008-09-12
PE20090111A1 (es) 2009-02-26
AR065495A1 (es) 2009-06-10
WO2008108958A3 (en) 2009-05-07
ZA200906062B (en) 2010-05-26
EP2114402A2 (en) 2009-11-11
KR20090127902A (ko) 2009-12-14
WO2008108958A8 (en) 2009-08-13
IL200639A0 (en) 2010-05-17
CL2008000593A1 (es) 2008-09-05
TW200843756A (en) 2008-11-16
AU2008223513A1 (en) 2008-09-12
JP2010520201A (ja) 2010-06-10
US20100144591A1 (en) 2010-06-10
WO2008108958A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
UY30610A1 (es) Moduladores de mglur5
GT200600426A (es) Formulacion novedosa
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
AR060755A1 (es) Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv)
CO6410287A2 (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
PA8779201A1 (es) Derivados de piridina
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY28253A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparación, medicamentos que comprenden este compuesto y su uso.
CL2007001175A1 (es) Compuestos derivados de triazol-pirrolidina sustituidos, moduladores de receptores de glutamato metabotropicos (mglur5); compuestos intermediarios; composicion y combinacion farmaceutica que los comprende; y uso de los compuestos en la preparacion de medicamentos para tratar enfermedades gastroesofagicas, la ansiedad y dolores.
UY31839A (es) Compuestos
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo